Viemed strategy seeks to re-inforce our position as a leader in the US home respiratory health care industry by improving the quality of life for its patients.
The company is well positioned to pursue sustainable growth and profitability through leveraging its brand awareness, realizing operational synergies, expansion of its product and service offerings and pursing growth into new US states not currently covered by Viemed.
In a very dynamic healthcare landscape, Viemed has managed to build a strong reputation through successful differentiation based on:
Strong financial performance
Proven clinical results patient outcomes
93% of patients report they breathe better
Patients are 3 times more likely to pass away during 90 days after a Chronic Respiratory failure diagnosis if NIV treatment is not obtained
Reduction of readmissions to facilities reduces cost to payers - currently estimated at approximately $30,000 per patient of annual savings
Viemed patients have on average a 5.4% re-admission rate to hospitals vs a 20% industry standard - a significant saving to hospitals and patients in time and resources
Attractive industry growth opportunity
At the age of 65, patients qualify for Medicare. 10,000 people turn 65 daily for the next 19 years.
Expenditures are expected to grow at a 5.3% CAGR from $46.5 billion to $60.2 billion in 2020
Acumen Capital Finance Partners, Ltd.
Beacon Securities Unlimited
Lake Street Capital Markets
Viemed’s public filings, including news releases, financial reports, management proxy circulars, and annual information forms, are available from The System for Electronic Document Analysis and Retrieval (SEDAR), an electronic filing system for Canadian publicly traded companies and the electronic data gathering, analysis and retrieval (EDGAR), an electronic filing system for US listed companies.
Access all of Viemed’s TSX regulatory filings on SEDAR: https://sedar.com/homepage_en.htm
Access all of Viemed’s NASDAQ regulatory filings on EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001729149&owner=exclude&count=40
NEWS AND EVENTS
3 March 2020
2019 Year End Earnings - Conference Call
5 November 2019
2019 Third Quarter Earnings Conference Call
9 August 2019
2019 Second Quarter Earnings Conference Call
7 May 2019
2019 First Quarter Earnings Conference Call
28 February 2019
2018 Year End Earnings - Conference Call
5 November 2018
2018 Third Quarter Earnings – Conference Call
14 August 2018
2018 Second Quarter Earnings – Conference Call
8 May 2018
2018 Quarterly Earnings – Conference Call
13 March 2018
2017 Year End Financial Results - Conference Call
IR PRESENTATION AND DOWNLOADS
PRESENTATION DECK & FACT SHEET
The following information was accurate at the time of posting but may be superseded by subsequent disclosure.
QUARTERLY AND CONFERENCE CALLS
Viemed hosts quarterly earnings calls. All replays will be posted following calls.
Viemed Healthcare follows and maintains high standards of Corporate Governance. The Board of Directors of Viemed Healthcare believes that good governance practices protect long-term shareholder value and ensure that the Company conducts its activities and operations with integrity and in an ethical manner, geared towards shareholders’ best interests.
NASDAQ STOCK INFORMATION
TSX STOCK INFORMATION
INVESTOR CONTACT FORM
SIGN UP HERE FOR AN INVESTOR PACK AND INFORMATION
If you would like to receive a corporate information package or for someone to contact you directly, please complete the form below and we will get back to you shortly:
Viemed is listed on the Toronto Stock Exchange (TSX) under the ticker symbol VMD
Transfer agent & registrar
Computershare Investor Services Inc.
2nd Floor, 510 Burrard Street,
Vancouver, British Columbia V6C 3A8.
Ernst & Young LLP
701 Poydras Street, Suite 3900
New Orleans, LA 70139